[A19-87] Risankizumab (plaque psoriasis) - Addendum to Commission A19-41
Last updated 22.11.2019
Project no.:
A19-87
Commission:
Commission awarded on 07.10.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Adults with moderate to severe plaque psoriasis
Result of dossier assessment:
Conclusion of dossier assessment A19-41 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-41 | Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G19-16 | Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41 | Commission completed |
Federal Joint Committee (G-BA)
2019-11-22 A G-BA decision was published.